1. Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study
- Author
-
Shahjada Selim, Muhammad Shah Alam, Samir Kumar Talukder, Md Lutful Kabir, Abu Jar Gaffar, Md Ahamedul Kabir, Nusrat Zarin, Shahin Ibn Rahman, Md Masud Un Nabi, Marufa Mustari, Md Firoj Hossain, Ahmed Ifrad Bin Raunak, Md Azizul Hoque, Md Rashedul Islam, Farhana Akter, Mohammad Abdul Hannan, Mohammad Saifuddin, Md Asaduzzaman, Mohammad Motiur Rahman, Afsar Ahammed, Md Abdur Rafi, Mohammad Jahid Hasan, and A. B. M. Kamrul-Hasan
- Subjects
Type 2 diabetes mellitus ,Dyslipidemia ,Hypercholesterolemia ,Lipid-lowering agent ,Lipid control ,Glycemic control ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Background Achievement of lipid targets is crucial in patients with type 2 diabetes mellitus (T2DM) to mitigate the risk of cardiovascular diseases (CVD). Data on lipid-control status among patients with T2DM in Bangladesh are scarce. This study was conducted to determine the lipid-control status among patients with T2DM who were on lipid-lowering drugs in the country. Methods This cross-sectional study was conducted in the diabetes outpatient departments of several tertiary hospitals in Bangladesh from January 2022 to December 2022. Adults of both sexes diagnosed with T2DM for at least one year and were on the lipid-lowering drug(s) for a minimum of 3 months were included in the study by consecutive sampling. Patients’ data were collected by face-to-face interviews, and blood samples were collected for fasting lipid profile. The lipid target was set at 40 mg/dL for high-density lipoprotein cholesterol (HDL-C), and
- Published
- 2023
- Full Text
- View/download PDF